Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Non Operating Income (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Non Operating Income for 12 consecutive years, with -$3000.0 as the latest value for Q1 2026.

  • For Q1 2026, Non Operating Income fell 100.07% year-over-year to -$3000.0; the TTM value through Mar 2026 reached $3.9 million, up 113.21%, while the annual FY2025 figure was $3.9 million, 111.76% up from the prior year.
  • Non Operating Income hit -$3000.0 in Q1 2026 for Cartesian Therapeutics, down from $3.9 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $4.2 million in Q1 2025 and bottomed at -$34.3 million in Q4 2024.
  • Average Non Operating Income over 5 years is -$1.6 million, with a median of $245000.0 recorded in 2023.
  • Year-over-year, Non Operating Income soared 25200.0% in 2023 and then tumbled 55206.45% in 2024.
  • Cartesian Therapeutics' Non Operating Income stood at $175000.0 in 2022, then crashed by 135.43% to -$62000.0 in 2023, then crashed by 55206.45% to -$34.3 million in 2024, then skyrocketed by 111.42% to $3.9 million in 2025, then crashed by 100.08% to -$3000.0 in 2026.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$3000.0, $3.9 million, and -$5000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.